The survey included responses from over one thousand medical cannabis patients, plus an analysis of trends in the medical cannabis market.
Image | adobe.stock/Soru Epotok
In an April 7, 2025, news release, the medical cannabis company Bloomwell Group GmbH announced results from a survey on sleeping disorders and cannabis compared with conventional sleeping medications (1). As Julian Wichmann M.D. Specialist and CEO of Bloomwell GmbH explains, the report, “The Cannabis-Barometer – Medical Cannabis as an Effective Therapy for Sleep Disorders” aimed to address misconceptions around medical cannabis use and patients. Bloomwell was founded in 2020 and is based in Frankfurt, Germany.
Data analyzed included 1086 anonymous responses from patients who had been using medical cannabis since 2023 for their sleep disorders. The survey was conducted from December 2024 to March 2025.
Highlighted results include:
"The data paints a very different picture than some critics who publicly question cannabis treatments prescribed via telemedicine platforms or dismiss sleep disorders as a 'mild' condition,” stated Dr. Wichmann, in the news release. “People with sleep disorders suffer greatly, often having tried numerous over-the-counter and prescription sleep aids over the years. Medical cannabis has proven to be far more effective in many cases, with fewer side effects. Rather than discrediting patients who choose medical cannabis as a treatment option, we should celebrate the fact that they finally have a real alternative with minimal or no side effects. After years of unsuccessful treatments and countless sleepless nights, patients now have an option that truly helps. This is especially important given the high abuse potential and dependence risk of commonly prescribed sleeping pills and sedatives like benzodiazepines and Z-drugs. In many cases, patients can now discontinue these medications."
Niklas Kouparanis explains how Germany’s Cannabis Act (CanG) is beginning to transform the country's medical cannabis market, with potential opportunities to expand telemedicine, improve physician training, and enhancing accessibility in this rapidly growing industry.
Additionally, Bloomwell also conducted a market analysis of medical cannabis in “The Cannabis-Barometer – Trends in Cannabis Flower Market – Q1 2025.” A six-figure number of prescriptions, filled through partner pharmacies in Germany, were analyzed anonymously.
Trends included:
"In 2024, the German medical cannabis industry gained global attention due to rapid growth that immediately followed the landmark reclassification of medical cannabis as a non-narcotic, which went into effect on April 1, 2024,” added Niklas Kouparanis, Co-Founder and CEO of Bloomwell Group. “This progressive policy update made medical cannabis therapy, including through telehealth services, more accessible to hundreds of thousands of patients. At the same time, costs along the entire value chain have dropped significantly. The industry has been able to pass these savings on to patients, so despite high demand, prices have stabilized to be very inexpensive by global standards. This democratization of therapy now allows the general public to access cannabis treatment without overburdening the healthcare system in terms of capacity or costs. As a result, Germany is on track to become the largest market for medical cannabis in the world, potentially surpassing one million patients this year. Innovative telemedicine is key to ensuring safe, effective medical care for those who have previously relied on unlicensed sources, despite the risks involved."
Resources
